Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
CLEVELAND, Feb. 09, 2016 -- Athersys, Inc. (Nasdaq:ATHX) will release its year end 2015 financial results at approximately 4:00 PM EST on Thursday, March 10, 2016, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | March 10, 2016 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | 800-273-1254 |
| Telephone access: International | 973-638-3440 |
| Access code | 22710392 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM EDT on March 24, 2016 at the aforementioned URL, or by dialing 800-585-8367 or 855-859-2056 in the U.S. and Canada, or from abroad 404-537-3406, and entering access code 22710392.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
